Efficacy of sorafenib combined with transarterial chemoembolization in the treatment of advanced hepatocellular carcinoma: A meta-analysis

doi:10.4251/wjgo.v17.i2.98927

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

(113)

(104)

(0)

(1)

(2697)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastrointest Oncol. Feb 15, 2025; 17(2): 98927
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.98927

Full Size Figure Download Figure

Figure 5 Sensitivity analysis graphs confirming the stability of the meta-analysis results for overall survival and progression-free survival. A: Overall survival; B: Progression-free survival.

Citation: Xu M, Zhou SR, Li YL, Zhang CH, Liao DZ, Wang XL. Efficacy of sorafenib combined with transarterial chemoembolization in the treatment of advanced hepatocellular carcinoma: A meta-analysis. World J Gastrointest Oncol 2025; 17(2): 98927
URL: https://www.wjgnet.com/1948-5204/full/v17/i2/98927.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i2.98927

Xu M, Zhou SR, Li YL, Zhang CH, Liao DZ, Wang XL. Efficacy of sorafenib combined with transarterial chemoembolization in the treatment of advanced hepatocellular carcinoma: A meta-analysis. World J Gastrointest Oncol 2025; 17(2): 98927 [PMID: 39958535 DOI: 10.4251/wjgo.v17.i2.98927]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.